Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Aevis Victoria SA is a Switzerland-based investment holding company founded in 2006 and headquartered in Fribourg. It specializes in the healthcare, hospitality, lifestyle, and infrastructure sectors, operating primarily through its Hospitals, Hospitality, and Real Estate segments. The company manages a diverse portfolio that includes private hospitals, hotels, radiology institutes, pharmacies, urology centers, health centers, day clinics, and golf courses, employing around 4,731 people. Notable offerings encompass health management programs, lifestyle coaching, and anti-aging cosmeuticals under the Nescens brand, alongside specialized services such as ambulance operations, physiotherapy, ophthalmology, sports medicine, medical radiation, stem cells, cosmetics, parking, cleaning, sterilization, and IT support. Aevis Victoria SA also owns strategic real estate properties supporting its healthcare and hospitality activities, with sales predominantly generated in Switzerland—reaching 883 million CHF in 2024, led by healthcare at 685 million CHF. As a subsidiary of M.R.S.I. Medical Research, Services and Investments S.A., which holds 75.59% ownership, it plays a key role in Switzerland's investment landscape, fostering advancements in life-enhancing services.
CHF 12.95
+CHF 0.00 (+0.00%)
EOD Aug 14, 2026
The business is unprofitable at the operating level (-1.31% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 18.4%, still solid.
Net debt of CHF 921M represents 188.9x FCF, leverage limits flexibility.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
CHF 1.20B
▲ +18.4% YoY
Net Income (TTM)
-CHF 26M
▼ -207.5% YoY
Op. Margin
-1.31%
▲ +1.1pp YoY
ROIC
-0.79%
▲ +0.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
CHF 5M
▲ +125.9% YoY
Op. Cash Flow (TTM)
CHF 91M
▲ +408.3% YoY
Net Debt
CHF 921M
Cash & Equiv.
CHF 29M
3Y CAGR: +3.2%
3Y CAGR: -50.5%
Continue Research
Aevis Victoria SA (AEVS.XSWX) trades above a two-stage DCF intrinsic value of about CHF -9.94 per share, so at CHF 12.95 the stock looks overvalued (176.8% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Aevis Victoria SA scores 25/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about CHF -9.94 per share for AEVS.XSWX, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around CHF -7.46. At today's CHF 12.95, that puts the stock about 176.8% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Aevis Victoria SA scores 25 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -1.3% operating margin and a -0.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. AEVS.XSWX currently trades above its estimated intrinsic value and scores 25/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.